Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Apogee Therapeutics's share price for the quarter that ended in Mar. 2024 was $66.45. Apogee Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 56.37 Mil. Therefore, Apogee Therapeutics's market cap for the quarter that ended in Mar. 2024 was $3,745.64 Mil.
Apogee Therapeutics's quarterly market cap
increased
from Sep. 2023 ($1,022.77 Mil) to Dec. 2023 ($1,355.63 Mil) and
increased
from Dec. 2023 ($1,355.63 Mil) to Mar. 2024 ($3,745.64 Mil).
Apogee Therapeutics's annual market cap
stayed the same
from . 20 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then
increased
from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($1,355.63 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Apogee Therapeutics's Enterprise Value for Today is $1,645.18 Mil.
Apogee Therapeutics Market Cap Historical Data
The historical data trend for Apogee Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Apogee Therapeutics's Market Cap
For the Biotechnology subindustry, Apogee Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apogee Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apogee Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Apogee Therapeutics's Market Cap falls into.
Apogee Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Apogee Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apogee Therapeutics (NAS:APGE) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Apogee Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Apogee Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Apogee Therapeutics (Apogee Therapeutics) Business Description
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two most advanced programs are APG777 and APG808, which they initially develop for treating AD and COPD, respectively. With its broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefits to patients underserved by today's standard of care.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
APGE has been successfully added to your